These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10987610)

  • 21. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy.
    Henein MY; O'Sullivan CA; Ramzy IS; Sigwart U; Gibson DG
    J Am Coll Cardiol; 1999 Oct; 34(4):1117-22. PubMed ID: 10520800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.
    Sathyamurthy I; Nayak R; Oomman A; Subramanyan K; Kalarical MS; Mao R; Ramachandran P
    Indian Heart J; 2014; 66(1):57-63. PubMed ID: 24581097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics and Outcome of Alcohol Septal Ablation With Confirmation by Nitroglycerin Test for Drug-Refractory Hypertrophic Obstructive Cardiomyopathy With Labile Left Ventricular Outflow Obstruction.
    Kitamura M; Takayama M; Matsuda J; Kubota Y; Nakamura S; Takano H; Asai K; Shimizu W
    Am J Cardiol; 2015 Sep; 116(6):945-51. PubMed ID: 26209114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy.
    Chang SM; Nagueh SF; Spencer WH; Lakkis NM
    J Am Coll Cardiol; 2003 Jul; 42(2):296-300. PubMed ID: 12875767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients.
    Lakkis N; Plana JC; Nagueh S; Killip D; Roberts R; Spencer WH
    Am J Cardiol; 2001 Sep; 88(5):583-6. PubMed ID: 11524078
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical and echocardiographic follow-up of patients with hypertrophic obstructive cardiomyopathy treated by percutaneous septal ablation].
    Delgado V; Sitges M; Andrea R; Rivera S; Masotti M; Francino A; Azqueta M; Paré C; Betriu A
    Rev Esp Cardiol; 2006 Nov; 59(11):1123-30. PubMed ID: 17144987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: an echocardiographic study].
    Rivera S; Sitges M; Azqueta M; Marigliano A; Velamazán M; Miranda-Guardiola F; Betriu A; Paré C
    Rev Esp Cardiol; 2003 Dec; 56(12):1174-81. PubMed ID: 14670269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Septal myectomy in hypertrophic obstructive cardiomyopathy: late results with stress echocardiography.
    Göl MK; Emir M; Keleş T; Küçüker SA; Birincioğlu CL; Karagöz YH; Kural T; Taşdemir O; Göksel S; Bayazit K
    Ann Thorac Surg; 1997 Sep; 64(3):739-45. PubMed ID: 9307467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Almasood A; Garceau P; Woo A; Rakowski H; Schwartz L; Overgaard CB
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1030-4. PubMed ID: 21939945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy.
    Hage FG; Karakus G; Luke WD; Suwanjutah T; Burri MV; Nanda NC; Aqel RA
    Echocardiography; 2008 Aug; 25(7):784-9. PubMed ID: 18754938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy.
    Finocchiaro G; Haddad F; Kobayashi Y; Lee D; Pavlovic A; Schnittger I; Sinagra G; Magavern E; Myers J; Froelicher V; Knowles JW; Ashley E
    Echocardiography; 2016 May; 33(5):686-94. PubMed ID: 26926154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; He ZX; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Roberts R; Verani MS; Kleiman NS; Spencer WH
    J Am Coll Cardiol; 1998 Jul; 32(1):225-9. PubMed ID: 9669274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
    [No Abstract]   [Full Text] [Related]  

  • 37. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Doppler echocardiographic evaluation of left ventricular diastolic function in patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation in acute and long-term follow up].
    Wojtarowicz A; Kornacewicz-Jach Z; Kaźmierczak J; Szamlewski P; Gil R; Lewandowski M
    Pol Merkur Lekarski; 2002 Jul; 13(73):25-8. PubMed ID: 12362500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy--the Baylor experience (1996-2002).
    Fernandes VL; Nagueh SF; Wang W; Roberts R; Spencer WH
    Clin Cardiol; 2005 Mar; 28(3):124-30. PubMed ID: 15813618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.